

Supplementary Material

Supplementary Table 1. Factors associated with uMRD attainment in the peripheral blood or bone marrow in patients who had not achieved uMRD after 12 months of venetoclax.

			Association with PB/BM uMRD attainment	
Variable		N=	Cause specific HR (95%CI)	P value
Age ≥ 65	Y	24	1.40 (0.49-4.00)	0.532
	N	17		
≥4 Prior Lines of Therapy	Y	15	0.55 (0.17-1.77)	0.307
	N	26		
Fludarabine Refractory	Y	17	0.30 (0.08-1.14)	0.061
	N	24		
Bulky Disease	Y	16	1.33 (0.45-3.93)	0.599
	N	25		
Rituximab Combination Therapy	Y	9	3.11 (1.00-9.73)	0.039
	N	34		
Dose ≥400 mg	Y	30	1.64 (0.44-5.76)	0.439
	N	11		
Del(17p) and / or <i>TP53</i> Mutation	Y	21	0.381 (0.13-1.11)	0.067
	N	19		
Complex Karyotype	Y	10	0.00 (undefined)	0.015
	N	19		
Prior navitoclax	Y	6	0.00 (undefined)	0.085
	N	35		

Supplementary Table 2. Factors associated with MRD recrudescence in the peripheral blood.

			Association with MRD recrudescence	
Variable		N=	HR (95%CI)	P value
Age \geq 65	Y	16	1.40 (0.43-4.59)	0.578
	N	10		
\geq 4 Prior Lines of Therapy	Y	8	2.71 (0.51-14.44)	0.225
	N	18		
Fludarabine Refractory	Y	9	0.54 (0.11-2.72)	0.457
	N	17		
Bulky Disease	Y	10	0.86 (0.20-3.78)	0.843
	N	16		
Rituximab Combination Therapy	Y	9	0.71 (0.17-2.94)	0.638
	N	17		
Dose \geq 400mg	Y	19	1.73 (0.33-8.91)	0.510
	N	7		
Del(17p) and / or <i>TP53</i> Mutation	Y	10	3.48 (0.75-16.08)	0.089
	N	14		
Complex Karyotype	Y	4	3.01 (0.66-14.39)	0.131
	N	13		
Prior navitoclax	Y	1	5.33 (0.58-49.21)	0.098
	N	25		
uMRD < 18 months	Y	14	1.13 (0.26-4.87)	0.873
	N	12		

Supplementary Figure 1.

Spaghetti plot of peripheral blood MRD burden after 24 months with ongoing venetoclax.

n=30. Curves terminated at time of last follow up or cessation of drug. Unrecordable MRD plotted at 0.0001 on y-axis.

